Clin Genitourin Cancer
-
Publication Venue For
- Impact of Concomitant Prostate Cancer Medications on Efficacy and Safety of Relugolix Versus Leuprolide in Men With Advanced Prostate Cancer. 2023
- Association of the Time to Immune Checkpoint Inhibitor (ICI) Initiation and Outcomes With Second Line ICI in Patients With Advanced Urothelial Carcinoma.. 20:558-567. 2022
- Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.. 20:e440-e452. 2022
- Patient- And Provider-Level Predictors of Survival Among Patients With Metastatic Renal Cell Carcinoma Initiating Oral Anticancer Agents.. 20:e396-e405. 2022
- Establishing metastatic prostate cancer quality indicators using a modified Delphi approach.. 20:e151-e157. 2022
- Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin.. 20:165-175. 2022
- Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era.. 20:107-113. 2022
- A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience.. 20:1-10. 2022
- PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma.. 18:509-513. 2020
- Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC).. 18:378-386.e1. 2020
- Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer.. 18:332-339.e2. 2020
- Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States.. 18:284-294. 2020
- Androgens and Overall Survival in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Docetaxel.. 18:222-229.e2. 2020
- Comparison of Neoadjuvant and Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer.. 18:201-209.e2. 2020
- Salvage Focal Cryotherapy Offers Similar Short-term Oncologic Control and Improved Urinary Function Compared With Salvage Whole Gland Cryotherapy for Radiation-resistant or Recurrent Prostate Cancer.. 18:e260-e265. 2020
- Androgen Receptor Splice Variant, AR-V7, as a Biomarker of Resistance to Androgen Axis-Targeted Therapies in Advanced Prostate Cancer.. 18:1-10. 2020
- Implications of Cystectomy Travel Distance for Hospital Readmission and Survival.. 17:e1171-e1180. 2019
- Salvage Radiotherapy for Recurrent Prostate Cancer: Can the Prognostic Grade Group System Inform Treatment Timing?. 17:e930-e938. 2019
- Salvage Prostate Cryoablation for the Management of Local Recurrence After Primary Cryotherapy: A Retrospective Analysis of Functional and Intermediate-Term Oncological Outcomes Associated With a Second Therapeutic Freeze.. 17:e831-e836. 2019
- A Complete Response After Pseudo-progression: Pembrolizumab for Metastatic Squamous Cell Carcinoma (SCC) of the Bladder.. 17:e672-e677. 2019
- Immunotherapy Is Changing First-Line Treatment of Metastatic Renal-Cell Carcinoma.. 17:e513-e521. 2019
- Prostate Cancer National Summit's Call to Action.. 17:161-168. 2019
- Incidental Detection of Metastatic Penile Squamous-Cell Carcinoma With Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid (18F-Fluciclovine) PET/CT in a Patient With Recurrent Prostate Cancer.. 17:e184-e186. 2019
- Statins are Associated With Increased Biochemical Recurrence After Radical Prostatectomy in Diabetic Men but no Association was Seen in Men also Taking Metformin: Results From the SEARCH Database.. 17:e140-e149. 2019
- Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma.. 16:341-348. 2018
- Does Any Racial Disparity Exist in Oncologic Outcomes After Primary Cryotherapy for Prostate Cancer? A Matched-pair Comparative Analysis of the Cryo On-Line Data Registry.. 16:e1073-e1076. 2018
- Predicting Cardiovascular Disease Among Testicular Cancer Survivors After Modern Cisplatin-based Chemotherapy: Application of the Framingham Risk Score.. 16:e761-e769. 2018
- Pazopanib in the Treatment of Bilateral Multifocal Renal Oncocytomas: A Case Report.. 16:e509-e512. 2018
- Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate.. 16:e477-e482. 2018
- Phase 2 Study of Weekly Paclitaxel Plus Estramustine in Metastatic Hormone-Refractory Prostate Carcinoma: ECOG-ACRIN Cancer Research Group (E1898) Trial.. 16:e315-e322. 2018
- Acute Myeloid Leukemia After Olaparib Treatment in Metastatic Castration-Resistant Prostate Cancer.. 15:e1137-e1141. 2017
- Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM.. 15:31-41.e4. 2017
- Resource Use in the Last Year of Life Among Patients Who Died With Versus of Prostate Cancer.. 14:28-37.e2. 2016
- Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer.. 13:e341-e345. 2015
- Complete Biochemical Response (Prostate Specific Antigen) to Sipuleucel-T in Metastatic Castrate-Resistant Prostate Cancer: A Case Report With Docetaxel Chemotherapy Administered Just Before Sipuleucel-T.. 13:e361-e364. 2015
- A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma.. 13:319-327. 2015
- Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer.. 13:392-399. 2015
- Deferred systemic therapy in patients with metastatic renal cell carcinoma.. 13:e159-e166. 2015
- Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer.. 12:317-324. 2014
- A phase Ib study of combined VEGFR and mTOR inhibition with vatalanib and everolimus in patients with advanced renal cell carcinoma.. 12:241-250. 2014
- "Real world" treatment of metastatic renal cell carcinoma in a joint community-academic cohort: progression-free survival over three lines of therapy.. 11:441-450. 2013
- A phase II trial of temsirolimus in men with castration-resistant metastatic prostate cancer.. 11:397-406. 2013
- Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.. 11:45-50. 2013
- Neutropenia as a potential pharmacodynamic marker for docetaxel-based chemotherapy in men with metastatic castration-resistant prostate cancer.. 10:239-245. 2012
- Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer.. 10:6-14. 2012
- Arsenic trioxide in recurrent urothelial cancer: a cancer and leukemia group B phase II trial (CALGB 99903).. 7:E66-E70. 2009